Survey of Patient Experiences during the COVID-19 Pandemic

AMMF and other members of the Cancer521 alliance of cancer charities and organisations have helped in the development of a survey of patients with rare and less common cancers to find out more about their experiences during the coronavirus pandemic. The survey is being organised by Cancer52, who will also analyse the results and share a full summary with all its charity members. The results of this surve...

Read More

FDA approves Pemigatinib for CCA

The US pharmaceutical company, Incyte, has gained accelerated approval from the FDA (the US Food and Drug Administration), for their targeted therapy Pemazyre (pemigatinib) for the treatment of cholangiocarcinoma, (bile duct cancer)1. This follows the outcome of the clinical trial, FIGHT-202, in which adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma w...

Read More

NHS Cancer Programme team and COVID-19 updates

AMMF’s CEO, Helen Morement is attending the weekly virtual COVID-19 briefing meetings with the NHS Cancer Programme team ... Today’s meeting (07.04.2020) was chaired by David Fitzgerald (Programme Director, NHS Cancer Programme), Peter Johnson (National Clinical Director for Cancer, NHS England and NHS Improvement), and Cally Palmer (National Cancer Director for NHS England and NHS Improvement). ...

Read More

COVID-19: An update from AMMF

This is an uncertain and worrying time for us all, but we realise that this must be especially so for all those with cholangiocarcinoma. AMMF is following government advice and, over the last couple of weeks, we have worked hard to put contingency plans in place to ensure our work can continue as smoothly as possible.  AMMF’s team is now working remotely and the charity continues, as always, to do all w...

Read More

The ABC-06 study – first results out …

The first results of the ABC-06 clinical trial were formally presented by Dr Angela Lamarca of The Christie NHS Foundation Trust at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on 2nd June 2019. ASCO hosts the largest global cancer conference with over 45,000 attendees, and the ABC-06 trial results were presented in front of an audience of approximately 5,000. Dr An...

Read More

Cholangiocarcinoma Experts of the Future!

Twelve aspiring medics from the Imperial College London School of Medicine who were involved in the new second year ‘Clinical Research and Innovation’ module, were selected to take part in a cholangiocarcinoma research experience in Khon Kaen, Thailand, in the summer of 2018. Tom O’Connor and Tom Hughes, members of the group of twelve, had already forged strong bonds with the Khon Kaen team during ...

Read More

Global Cholangiocarcinoma Alliance launched!

A new, collective voice for cholangiocarcinoma, the Global Cholangiocarcinoma Alliance (GCA) was heard for the first time on World Cholangiocarcinoma Day, 12 February, 2019. Plans were announced to form the world’s first global cholangiocarcinoma alliance back in September 2018, at AMMF’s international workshop held at Imperial College London and attended by the six inaugural partners of World Chol...

Read More

The NHS ‘Long Term Plan’ is published

In its ambitious plan, the NHS makes relatively few cancer commitments but, promisingly, takes an ‘all cancer’ approach, which by definition includes rare and less common cancers, instead of previous approaches which have sometimes prioritised the four more common cancers. The plan also focuses on moving more care into the community and out of hospital, accompanied by increased funding for primary an...

Read More

AMMF’s Year in Review – highlights of 2018

The last year has been an exceptionally busy year for AMMF, and the following are just some of the highlights:   AMMF’s Cholangiocarcinoma Conference   International Cholangiocarcinoma Workshop   Data Analysis Project – and a new data analyst   Research funding awarded   Cholangiocarcinoma-UK AMMF’s Cholangiocarcinoma Conference We welcomed a record number of delegate...

Read More

AMMF’s Response to NHS England’s Draft Commissioning Policy re SIRT for Intrahepatic Cholangiocarcinoma

NHS-funded SIRT (selective internal radiation therapy) had been available for patients with intrahepatic cholangiocarcinoma through the CtE (Commissioning through Evaluation) programme until this funding was withdrawn on 31st March 2017 ‘to be evaluated’. In June 2018, NICE issued their draft Interventional Procedures Guide (IPG) for comment regarding the safety and efficacy of intrahepatic chola...

Read More